Join to View Full Profile
9200 W Wisconsin Ave# HematoloMilwaukee, WI 53226
Phone+1 414-805-3666
Fax+1 414-805-6815
Dr. Dhakal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Binod Dhakal, MD, MS, is Associate Professor of Medicine, at the Medical College of Wisconsin, Division of Hematology, specializing in multiple myeloma and plasma cell disorders.
His focus has been high-risk myeloma, kidney disease, and immunotherapy. He has served as the principal investigator for multiple CAR-T trials, including studies on BCMA and GPRC5D-targeted therapies, contributing to the FDA approval of Cilta-cel. Additionally, he is involved in clinical trials for small-molecule inhibitors like Sonrotoclax. As a core member of the Blood & Marrow Transplant Clinical Trials Network (BMT CTN), he co-leads national trials that explores a novel CAR-T and bispecific antibody combination for high-risk myeloma. His experience underscores the importance of clinical trials, collaboration, and mentorship in advancing myeloma treatment.
Education & Training
Medical College of Wisconsin Affiliated HospitalsFellowship, Hematology and Medical Oncology, 2013 - 2016
Ascension Illinois/Saint FrancisResidency, Internal Medicine, 2007 - 2010
Manipal College of Medical ScienceClass of 2004
Certifications & Licensure
WI State Medical License 2010 - 2025
IL State Medical License 2007 - 2011
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed And/or Refractory Multiple Myeloma Start of enrollment: 2022 Jan 10
Roles: Contact, Principal Investigator
- MM CAR-T to Upgrade Response BMTCTN1902 Start of enrollment: 2022 Jan 05
Roles: Contact
- RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma Start of enrollment: 2020 Dec 02
Roles: Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsComparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.Doris K Hansen, Lauren C Peres, Danai Dima, Alicia Richards, Leyla Shune
Journal of Clinical Oncology. 2025-05-01 - Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma.Meera Mohan, Aniko Szabo, Heloise Cheruvalath, Anna Clennon, Vineel Bhatlapenumarthi
Blood Cancer Journal. 2025-04-23 - Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection ...Susan Bal, Tylan Magnusson, Gayathri Ravi, Smith Giri, Kelly Godby
Blood Cancer Journal. 2025-04-23
Press Mentions
Carvykti Lowering Risk of Death as Second-Line Myeloma Therapy: TrialOctober 1st, 2024- CARVYKTI® Is the First and Only Cell Therapy to Significantly Extend Overall Survival Versus Standard Therapies for Patients with Multiple Myeloma as Early as Second LineSeptember 27th, 2024
- CtDNA Possible Biomarker to Predict Relapse in Multiple MyelomaAugust 11th, 2021
- Join now to see all
Professional Memberships
- Member
Other Languages
- Hindi, Urdu
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
